Sanjeev Thohan

Nonclinical SME (LO to EOP1) - Creatively Prosecuting Science. Funder/Board Member/Entrepreneur/Mentor/Corporate Strategy and Escape Velocity Calculations Scilosopher at large - Pick a topic Opinions are mine alone.

Sanjeev Thohan is a highly experienced research scientist and pharmaceutical industry professional currently serving as the Chief Scientific Officer at LatentSpace Therapeutics.1 With a career spanning over 25 years, Thohan has held various leadership positions in drug development, preclinical research, and toxicology across multiple pharmaceutical companies.

Career Highlights

Thohan's professional journey includes significant roles such as:

Senior Vice President of Nonclinical Research at Alterome Therapeutics1
Vice President of Nonclinical Development at Kinnate Biopharma1
Senior Director of Preclinical Safety at Xeris Pharmaceuticals1
Research Fellow in Toxicology and Translational Sciences at Novartis1
Research Director of DMPK/Toxicology Preclinical Development at Exelixis1

Expertise and Contributions

Sanjeev Thohan is known for his expertise in:

Nonclinical drug development
Preclinical safety assessment
Toxicology
Drug metabolism and pharmacokinetics (DMPK)
Translational sciences

He describes himself as a "Nonclinical SME (LO to EOP1)" who is "Creatively Prosecuting Science".1 This suggests his focus on nonclinical aspects of drug development from lead optimization (LO) to end of phase 1 (EOP1) clinical trials.

Additional Roles

Beyond his primary career, Thohan is involved in various advisory and entrepreneurial activities:

Founder of SARx Consulting1
Scientific Advisory Board Member for Phoenix Molecular Designs and Cogentis Therapeutics1
Mentor at The Center for Advancing Innovation Inc.1

Sanjeev Thohan's LinkedIn profile demonstrates his extensive experience and ongoing involvement in the pharmaceutical and biotechnology industries, with a particular focus on nonclinical research and drug development.